Medications

Britain snubs costly Novartis blood cancer drug

British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.

Oncology & Cancer

Improved survival for patients with chronic blood diseases

(Medical Xpress) -- New research from Karolinska Institutet shows that the survival for patients with chronic myeloproliferative diseases has improved in recent decades. This is despite the fact that no targeted drugs have ...

Oncology & Cancer

Drug offers relief for symptoms of myelofibrosis

People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the ...

page 2 from 3